AGP Executive Report
Last update: 2 hours agoProvider Regulation: CMS proposed removing outdated requirements for hospitals and other providers, including some COVID-19 reporting rules, while adding consent protections for birth-tissue collection. Cancer Treatment: The FDA approved a five-minute injected form of amivantamab for recurrent or metastatic head and neck cancer, offering a new option for patients with limited treatments. Workforce: A new partnership between the Healthy Workforce Institute and Virginia Nurses Association aims to tackle workplace bullying and improve retention; NHS Wales is also developing a long-term staffing strategy. Industry Moves: CVS plans to split its $117 billion business, separating its pharmacy operations from health insurance. Boehringer Ingelheim also signed a deal worth up to $7 billion for oncology programs. Market Results: GE HealthCare and Stryker reported third-quarter sales growth, while GE raised its full-year outlook. Drug Supply: A survey found open manufacturing investigations delayed batch releases at 80% of Indian pharmaceutical plants surveyed, with some investigations taking up to six months.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
